The potential economic impact of restricted access to angiotensin-receptor blockers.
BACKGROUND
The use of angiotensin-receptor blockers increased by more than 4000% in Canada from 1996 to 2006. The benefit of these medications over angiotensin-converting-enzyme (ACE) inhibitors has not been proven aside from a reduction in dry cough. We estimated the potential cost savings that might have been achieved had access to angiotensin-receptor blockers been restricted.


METHODS
We performed a cost-minimization analysis with a decision-tree model using a societal perspective over a one-year period. Sources of data for model parameters included IMS Health Canada data collected from one-third of all retail pharmacies for the cost and use of angiotensin-receptor blockers and ACE inhibitors in each province, as well as published studies for administrative costs and incidence of dry cough. We used Monte Carlo simulations with 10 000 iterations to test the impact of several model parameters (e.g., drug prices, administrative costs and the incidence of dry cough). All data are in 2006 Canadian dollars.


RESULTS
A policy that would have restricted access to angiotensin-receptor blockers might have saved more than $77 million in Canada in 2006. The simulations yielded similar savings for the year (mean $58.3 million, 95% confidence interval $29.3 million to $90.8 million). Every simulation showed a cost savings.


CONCLUSIONS
Had access to angiotensin-receptor blockers been restricted, the potential cost savings to the Canadian health care system might have been more than $77 million in 2006, likely without any adverse effect on cardiovascular health.
Centre de recherche du Centre hospitalier de l’Université de Montréal, Que., Canada.
Jason R
JR
Guertin
Cynthia A
CA
Jackevicius
Jafna L
JL
Cox
Karin
K
Humphries
Louise
L
Pilote
Derek Y
DY
So
Jack V
JV
Tu
Harindra
H
Wijeysundera
Stéphane
S
Rinfret
D057911:Angiotensin Receptor Antagonists / Q000191:economics*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000191:economics; D001955:British Columbia; D002170:Canada; D057186:Comparative Effectiveness Research; D003198:Computer Simulation; D003363:Cost Control; D003362:Cost-Benefit Analysis; D003371:Cough / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D003663:Decision Trees; D016527:Drug Costs; D006801:Humans; D015994:Incidence; D017059:Models, Econometric; D009010:Monte Carlo Method
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors
Ann Intern Med. 2008 Jan 1;148(1):16-29
17984484
Ann Intern Med. 2004 Nov 2;141(9):693-704
15520426
N Engl J Med. 2008 Oct 23;359(17):1802-10
18946065
CMAJ. 2009 Jul 7;181(1-2):E19-28
19581604
Lancet. 2002 Mar 23;359(9311):995-1003
11937178
J Am Coll Cardiol. 2008 Oct 28;52(18):1490-1
19017517
JAMA. 2007 Jul 4;298(1):61-9
17609491
N Engl J Med. 2008 Apr 10;358(15):1547-59
18378520
Lancet. 2004 Nov 6-12;364(9446):1684-9
15530629
N Engl J Med. 2008 Apr 24;358(17):1819-28
18375999
Med Care. 2004 Jul;42(7):653-60
15213490
Chest. 2006 Jan;129(1 Suppl):169S-173S
16428706
Can J Clin Pharmacol. 2009 Winter;16(1):e151-5
19193969
Health Policy. 2010 Mar;94(3):221-9
19879009
Ann Intern Med. 2004 Jul 20;141(2):102-12
15262665
Arch Intern Med. 2004 Apr 26;164(8):910-3
15111379
CMAJ. 2008 Feb 12;178(4):413-20
18268267